ACTH for Fatigue in Multiple Sclerosis Patients (ACTH)

• ClinicalTrials.gov Identifier: NCT02315872
• Recruitment Status: Completed
• First Posted: December 12, 2014
• Results First Posted: August 13, 2019
• Last Update Posted: September 9, 2019
• Sponsor: Providence Health & Services
• Collaborator: Mallinckrodt
• Information provided by (Responsible Party): Providence Health & Services

Study Description

Brief Summary:

This is a study of Acthar gel (ACTH) in patients with relapsing multiple sclerosis who are experiencing chronic fatigue.

Condition or disease	Intervention/treatment	Phase
Multiple Sclerosis, Relapsing-Remitting	Drug: ACTH; Drug: Placebo	Phase 3

Detailed Description:

This is a multi-center, randomized, double-blind, placebo-controlled study to demonstrate the safety, tolerability, and effect of ACTH on fatigue in patients with relapsing multiple sclerosis (RMS). The primary objective of this study is to assess the efficacy of ACTH versus placebo in reducing fatigability in patients with RMS. Secondary objectives include assessment of the tolerability and safety of twice-weekly ACTH treatment vs. placebo and evaluation of ACTH on depression, sleepiness, and quality of life measures and correlations between these measures.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 8 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: The Effect of ACTH (Acthar) on Measures of Chronic Fatigue in Patients With Relapsing Multiple Sclerosis.
• Actual Study Start Date: May 22, 2015
• Actual Primary Completion Date: June 20, 2017
• Actual Study Completion Date: December 13, 2018

Arms and Interventions

Arm	Intervention/treatment
Experimental: ACTH; The study drug (ACTH 40 units) will be given subcutaneously twice weekly for 2 weeks. If the patient tolerates this dosage regimen, the dose will be increased to 80 units twice weekly. If the 80 unit dosage is not tolerated, the dosage will be reduced to 40 units twice weekly for the remainder of the 24 week participation. The weekly doses will be given 3 days apart, for example, on every Monday and Thursday or every Tuesday and Friday.	Drug: ACTH; ACTH injections twice weekly for 28 weeks.; Other Names: Acthar Gel; Repository Corticotropin Injection
Placebo Comparator: Placebo; Placebo will be given subcutaneously twice weekly for 28 weeks.	Drug: Placebo; Placebo injections twice weekly for 28 weeks.; Other Name: Control

Outcome Measures

Primary Outcome Measures :

1. Fatigue at 28 Weeks [ Time Frame: 28 weeks ]
   Patient-reported levels of fatigue as measured by score on the Modified Fatigue Impact Scale (MFIS) and the Fatigue Severity Scale (FSS) at 28 weeks. The full-length MFIS consists of 21 items. A higher score on the MFIS indicates a greater impact of fatigue on a patient's activities. The FSS is a 9-item scale which measures the severity of fatigue and its effect on a person's activities and lifestyle in patients with a variety of disorders. Higher scores on each scale indicate a greater severity of fatigue.

Secondary Outcome Measures :

1. Depression at 28 Weeks [ Time Frame: 28 weeks ]
   Patient-reported depression as measured by the Beck Depression Inventory-II (BDI-II) at 28 weeks. The BDI-II is a 21-item self-report multiple-choice inventory used as an indicator of the severity of depression. A higher score indicates a greater severity of depression.
2. Sleepiness at 28 Weeks [ Time Frame: 28 weeks ]
   Patient-reported daytime sleepiness as measure by the Epworth Sleepiness Scale (ESS) at 28 weeks. The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life, or their 'daytime sleepiness'.
3. Quality of Life at 28 Weeks [ Time Frame: 28 weeks ]
   Patient-reported quality of life as measured by the 36-Item Short Form Health Survey (SF-36) at 28 weeks. The SF-36 is a 36-item, patient-reported survey of patient mental and physical health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Have documented diagnosis of Relapsing MS as defined by McDonald Criteria 2011 Revision for at least 6 months
• Have been treated with interferon beta 1a or 1b, glatiramer acetate, fingolimod, dimethyl fumarate, or teriflunomide for at least 6 months, with reported adherence rate of at least 75%, at time of screening
• Have an Kurtzke Expanded Disability Status Scale (EDSS) score of 0 to 4, inclusive
• Have Modified Fatigue Impact Scale (MFIS) ≥ 38 or Functional Systems Scores (FSS) ≥ 36, Beck Depression Inventory-II (BDI-II) greater than or equal to 19, and Expanded Disability Status Scale (EDSS) greater than or equal to 9
• Women of childbearing potential must employ proven methods to prevent pregnancy during the course of the trial
• Able to understand the purpose and risks of the study
• Must be willing to sign an inform consent
• Must be willing to follow the protocol requirements
• Subject must agree not to receive any live or live-attenuated vaccine during the trial

Exclusion Criteria:

• Have any of the contraindications for Acthar Gel as listed in the approved label, including sensitivity to proteins of porcine origin.
• Had treatment of systemic or oral corticosteroids of any type in 90 days prior to baseline/randomization
• Had a relapse or documented objective neurologic worsening in 90 days prior to baseline/randomization
• Has concurrent neurological disease other than multiple sclerosis
• History of sleep apnea
• History (within 90 days) of nocturnal pain and / or nocturnal spasms that interferes with or disrupts sleep, or uncontrolled nocturnal restless leg syndrome
• History of psychosis, bipolar disorder, mania/hypomania
• History of coronary heart disease, congestive heart failure, chronic pulmonary disease, emphysema, anemia, bleeding disorder, gastrointestinal bleeding, intestinal ulcer, clinically significant cardiac arrhythmia, Type I or II diabetes, uncontrolled hypertension, seizure disorder, cardiac arrhythmia, immune deficiency disorder, HIV-AIDS, tuberculosis, or dysthyroidal state (patients with a history of hypothyroidism or hyperthyroidism, which has been corrected to physiological levels will not be excluded)
• History of substance abuse, other than tobacco within the past 5 years or current alcohol dependence
• Current use of cannabis, opiates, benzodiazepines, barbiturates, gabapentin, pregabalin, topiramate, divalproex sodium, carbamazepine, oxcarbazepine, or any gaba-ergic medications other than tizanidine or Baclofen, which are permitted for spasticity treatment
• History of any malignant neoplasm except for past basal cell or squamous cell carcinoma of the skin, that has been successfully treated prior to the screening visit
• History of psychosis or history of use of neuroleptics including, but not restricted to, haloperidol, chlorpromazine, aripiprazole, olanzapine, risperidone
• History of suicide attempt, current suicidal thinking or is preparing for suicide
• Current use of Amphetamines or methylphenidate
• Current use of modafinil, or armodafinil
• Current use of amantidine

• The subject must have had a medication-free interval of:

  a. 7 days for prior use of: i. methylphenidate, amphetamine or dextroamphetamine ii. modafinil or armodafinil iii. diphenhydramine, phenylephrine, loratadine iv. gabapentin, pregabalin, topiramate, valproate/divalproex v. oxcarbazepine vi. codeine, hydrocodone, oxycodone, diphenhydramine, phenylephrine, gabapentin, pregabalin, topiramate, valproate/divalproex, oxcarbazepine, codeine, hydrocodone, oxycodone b. 14 days for prior use of: i. desloratadine ii. Amantidine iii. alprazolam, lorazepam, morphine, hydromorphone, amantidine, alprazolam, lorazepam iv. morphine, hydromorphone c. 28 days for prior use of: i. clonazepam ii. cannabis or other cannabinoids d. 90 days for prior use of carbamazepine

Contacts and Locations

Locations

United States, Alabama

North Central Neurology Associates, PC

Cullman, Alabama, United States, 35058

United States, Oregon

Providence Medical Group - Medford Neurology

Medford, Oregon, United States, 97504

Providence St. Vincent Medical Center

Portland, Oregon, United States, 97225

United States, Washington

Swedish Medical Center

Seattle, Washington, United States, 98122

MultiCare Health System -- Institute for Research and Innovation

Tacoma, Washington, United States, 98405

Sponsors and Collaborators

Providence Health & Services

Mallinckrodt

Investigators

• Principal Investigator: Stanely Cohan, MD, PhD; Providence Health & Services

  Study Documents (Full-Text)

Documents provided by Providence Health & Services:

Study Protocol and Statistical Analysis Plan  [PDF] December 30, 2015

More Information

Additional Information:

Providence Health & Services Brain and Spine Institute 

• Responsible Party: Providence Health & Services
• ClinicalTrials.gov Identifier: NCT02315872
• Other Study ID Numbers: 13-120A
• First Posted: December 12, 2014
• Results First Posted: August 13, 2019
• Last Update Posted: September 9, 2019
• Last Verified: August 2019

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

Keywords provided by Providence Health & Services:

Multiple Sclerosis; Acthar Gel; ACTH; Fatigue

Additional relevant MeSH terms:

Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Sclerosis; Fatigue; Pathologic Processes; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Adrenocorticotropic Hormone; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs